AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cetrorelix 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| gonadotropin-releasing-hormone (GnRH) inhibitors, peptides | 583 | 120287-85-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
LHRH antagonist
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.25 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 8 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 3 % | Benet LZ, Broccatelli F, Oprea TI |
| Vd (Volume of distribution) | 0.39 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.14 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 12 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 11, 2000 | FDA | EMD SERONO INC | |
| April 12, 1999 | EMA | MERCK EUROPE B.V. | |
| April 20, 2006 | PMDA | NIPPON KAYAKU CO., LTD. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 888.69 | 58.78 | 131 | 779 | 5731 | 90621806 |
| Premature ovulation | 235.89 | 58.78 | 23 | 887 | 7 | 90627530 |
| Blood luteinising hormone increased | 134.64 | 58.78 | 16 | 894 | 115 | 90627422 |
| Ascites | 99.25 | 58.78 | 31 | 879 | 47709 | 90579828 |
| Abortion spontaneous | 83.37 | 58.78 | 28 | 882 | 54028 | 90573509 |
| Blood oestrogen increased | 74.01 | 58.78 | 10 | 900 | 215 | 90627322 |
| Drug level decreased | 70.96 | 58.78 | 17 | 893 | 9713 | 90617824 |
| Ovarian disorder | 60.08 | 58.78 | 10 | 900 | 897 | 90626640 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 886.70 | 56.62 | 122 | 586 | 5238 | 110583353 |
| Premature ovulation | 136.99 | 56.62 | 13 | 695 | 7 | 110588584 |
| Blood luteinising hormone increased | 96.44 | 56.62 | 12 | 696 | 213 | 110588378 |
| Ascites | 88.87 | 56.62 | 30 | 678 | 92778 | 110495813 |
| Blood oestrogen increased | 79.22 | 56.62 | 10 | 698 | 200 | 110588391 |
| Drug level decreased | 67.71 | 56.62 | 17 | 691 | 18531 | 110570060 |
| Pelvic fluid collection | 63.29 | 56.62 | 10 | 698 | 1023 | 110587568 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H01CC02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones |
| FDA PE | N0000008638 | Decreased GnRH Secretion |
| FDA MoA | N0000175084 | Gonadotropin Releasing Hormone Receptor Antagonists |
| MeSH PA | D005300 | Fertility Agents, Female |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D012102 | Reproductive Control Agents |
| FDA EPC | N0000175839 | Gonadotropin Releasing Hormone Receptor Antagonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:59229 | GnRH antagonist |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
Related Drugs by ATC class:
H01CC Anti-gonadotropin-releasing hormones 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevention of premature ovulation during controlled ovarian stimulation | indication | 732970000 | |
| Premature Luteinizing Hormone Surges | indication | ||
| Prevention of premature ovulation | indication | ||
| Acute nephropathy | contraindication | 58574008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.65 | acidic |
| pKa2 | 12.09 | acidic |
| pKa3 | 12.45 | acidic |
| pKa4 | 13.01 | acidic |
| pKa5 | 13.29 | acidic |
| pKa6 | 13.37 | acidic |
| pKa7 | 13.67 | acidic |
| pKa8 | 13.71 | acidic |
| pKa9 | 10.75 | Basic |
| pKa10 | 5.35 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Gonadotropin-releasing hormone receptor | GPCR | ANTAGONIST | Ki | 8.80 | CHEMBL | CHEMBL | |||
| Lutropin-choriogonadotropic hormone receptor | GPCR | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D01685 | KEGG_DRUG |
| 130143-01-0 | SECONDARY_CAS_RN |
| 259338 | RXNORM |
| C0209366 | UMLSCUI |
| CHEBI:59224 | CHEBI |
| CHEMBL1200490 | ChEMBL_ID |
| CHEMBL2103735 | ChEMBL_ID |
| DB00050 | DRUGBANK_ID |
| C062876 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1190 | IUPHAR_LIGAND_ID |
| 6661 | INN_ID |
| OON1HFZ4BA | UNII |
| 25074887 | PUBCHEM_CID |
| 15671 | MMSL |
| 362200 | MMSL |
| 37942 | MMSL |
| d04706 | MMSL |
| 007799 | NDDF |
| 007800 | NDDF |
| 326083001 | SNOMEDCT_US |
| 395906005 | SNOMEDCT_US |
| 412114000 | SNOMEDCT_US |
| 4021277 | VANDF |
| 4024232 | VANDF |
| OON1HFZ4BA | INXIGHT DRUGS |
Pharmaceutical products:
None